7 results on '"Hirsch GS"'
Search Results
2. The possible role of the kynurenine pathway in adolescent depression with melancholic features.
- Author
-
Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM, Babb JS, Hirsch GS, and Liebes L
- Subjects
- 3-Hydroxyanthranilic Acid metabolism, Adolescent, Child, Cytokines blood, Depressive Disorder diagnosis, Depressive Disorder psychology, Depressive Disorder, Major diagnosis, Depressive Disorder, Major psychology, Enzyme Induction, Female, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase blood, Inflammation Mediators blood, Male, Neurotoxins blood, Reference Values, Tryptophan blood, Young Adult, Depressive Disorder physiopathology, Depressive Disorder, Major physiopathology, Kynurenine blood
- Abstract
Background: Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD and NonM-MDD) have distinct biological features in the kynurenine pathway (KP). The KP is initiated by pro-inflammatory cytokines via induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan (TRP) into kynurenine (KYN). KYN is further metabolized into neurotoxins linked to neuronal dysfunction in MDD. Hypotheses were that, compared to healthy controls and to NonM-MDD adolescents, adolescents with M-MDD would exhibit: (i) increased activation of the KP [i.e., increased KYN and KYN/TRP (reflecting IDO activity)]; (ii) greater neurotoxic loads [i.e., increased 3-hydroxyanthranilic acid (3-HAA, neurotoxin) and 3-HAA/KYN (reflecting production of neurotoxins)]; and (iii) decreased TRP. We also examined relationships between severity of MDD and KP metabolites., Methods: Subjects were 20 adolescents with M-MDD, 30 adolescents with NonM-MDD, and 22 healthy adolescents. MDD episode duration had to be >or= 6 weeks and Children's Depression Rating Scale-Revised (CDRS-R) scores were >or= 36. Blood samples were collected at AM after an overnight fast and analyzed using high-performance liquid chromatography. Group contrasts relied on analysis of covariance based on ranks, adjusted for age, gender, and CDRS-R scores. Analyses were repeated excluding medicated patients. Fisher's protected least significant difference was used for multiple comparisons., Results: As hypothesized, KYN/TRP ratios were elevated and TRP concentrations were reduced in adolescents with M-MDD compared to NonM-MDD adolescents (p = .001 and .006, respectively) and to healthy controls (p = .008 and .022, respectively). These findings remained significant when medicated patients were excluded from the analyses. Significant correlations were obtained exclusively in the M-MDD group between KYN and 3-HAA/KYN and CDRS-R., Conclusions: Findings support the notion that adolescent M-MDD may represent a biologically distinct clinical syndrome.
- Published
- 2010
- Full Text
- View/download PDF
3. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
- Author
-
March J, Silva S, Curry J, Wells K, Fairbank J, Burns B, Domino M, Vitiello B, Severe J, Riedal K, Goldman M, Feeny N, Findling R, Stull S, Baab S, Weller EB, Robbins M, Weller RA, Jessani N, Waslick B, Sweeney M, Dublin R, Walkup J, Ginsburg G, Kastelic E, Koo H, Kratochvil C, May D, LaGrone R, Vaughan B, Albano AM, Hirsch GS, Podniesinki E, Chu A, Reincecke M, Leventhal B, Rogers G, Jacobs R, Pathak S, Wells J, Lavanier SA, Danielyan A, Rohde P, Simons A, Grimm J, Frank S, Emslie G, Kennard B, Hughes C, Mayes TL, Rosenberg D, Benazon N, Butkus M, and Bartoi M
- Subjects
- Adolescent, Child, Combined Modality Therapy, Depressive Disorder, Major drug therapy, Depressive Disorder, Major psychology, Double-Blind Method, Female, Fluoxetine adverse effects, Follow-Up Studies, Humans, Longitudinal Studies, Male, Selective Serotonin Reuptake Inhibitors adverse effects, Severity of Illness Index, Treatment Outcome, United States, Cognitive Behavioral Therapy, Depressive Disorder, Major therapy, Fluoxetine therapeutic use, Selective Serotonin Reuptake Inhibitors therapeutic use
- Abstract
Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. The authors report effectiveness outcomes across a 1-year naturalistic follow-up period., Method: The randomized, controlled trial was conducted in 13 academic and community sites in the United States. Stages I, II, and III consisted of 12, 6, and 18 weeks of acute, consolidation, and continuation treatment, respectively. Following discontinuation of TADS treatments at the end of stage III, stage IV consisted of 1 year of naturalistic follow-up. The participants were 327 subjects between the ages of 12 and 17 with a primary DSM-IV diagnosis of major depressive disorder. No TADS treatment was provided during the follow-up period; treatment was available in the community. The primary dependent measures, rated by an independent evaluator blind to treatment status, were the total score on the Children's Depression Rating Scale-Revised and the rate of response, defined as a rating of much or very much improved on the Clinical Global Impressions improvement measure., Results: Sixty-six percent of the eligible subjects participated in at least one stage IV assessment. The benefits seen at the end of active treatment (week 36) persisted during follow-up on all measures of depression and suicidality., Conclusions: In contrast to earlier reports on short-term treatments, in which worsening after treatment is the rule, the longer treatment in the TADS was associated with persistent benefits over 1 year of naturalistic follow-up.
- Published
- 2009
- Full Text
- View/download PDF
4. Immune system dysregulation in adolescent major depressive disorder.
- Author
-
Gabbay V, Klein RG, Alonso CM, Babb JS, Nishawala M, De Jesus G, Hirsch GS, Hottinger-Blanc PM, and Gonzalez CJ
- Subjects
- Adolescent, Child, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Reference Values, Young Adult, Cytokines blood, Depressive Disorder, Major immunology, Th1 Cells immunology, Th2 Cells immunology
- Abstract
Background: A large body of evidence suggests that immune system dysregulation is associated with Major Depressive Disorder (MDD) in adults. This study extends this work to adolescent MDD to examine the hypotheses of immune system dysregulation in adolescents with MDD, as manifested by significantly: (i) elevated plasma levels of cytokines (interferon [IFN]-gamma, tumor necrosis factor-alpha, interleukin [IL]-6, IL-1beta, and IL-4); and (ii) Th1/Th2 cytokine imbalance shifted toward Th1 as indexed by increased IFN-gamma/IL-4., Method: Thirty adolescents with MDD (19 females; 13 medication-free/naïve; ages 12-19) of at least 6 weeks duration and a minimum severity score of 40 on the Children's Depression Rating Scale-Revised, and 15 healthy comparisons (8 females), group-matched for age, were enrolled. Plasma cytokines were examined using enzyme-linked immunosorbent assay. Mann-Whitney test was used to compare subjects with MDD and controls., Results: Adolescents with MDD had significantly elevated plasma IFN-gamma levels (3.38+/-11.8 pg/ml versus 0.37+/-0.64 pg/ml; p<0.003), and IFN-gamma/IL-4 ratio (16.6+/-56.5 versus 1.76+/-2.28; p=0.007). A trend for IL-6 to be elevated in the MDD group was also observed (1.52+/-2.88 pg/ml versus 0.49+/-0.90 pg/ml; p=0.09). Importantly, findings remained evident when medicated subjects were excluded., Conclusions: Findings suggest that immune system dysregulation may be associated with adolescent MDD, with an imbalance of Th1/Th2 shifted toward Th1, as documented in adult MDD. Larger studies with medication-free adolescents should follow.
- Published
- 2009
- Full Text
- View/download PDF
5. Endoscopic treatment of biliary leakage after laparoscopic cholecystectomy.
- Author
-
Raijman I, Catalano MF, Hirsch GS, MacFadyen B, Broughan TA, Chung RS, and Sivak MV Jr
- Subjects
- Adult, Aged, Cholangiopancreatography, Endoscopic Retrograde, Female, Humans, Intraoperative Complications diagnosis, Male, Middle Aged, Sphincterotomy, Endoscopic, Treatment Outcome, Biliary Tract injuries, Cholecystectomy, Laparoscopic adverse effects, Intraoperative Complications therapy
- Abstract
Laparoscopic cholecystectomy is an effective and safe treatment for uncomplicated symptomatic cholelithiasis. However, biliary tract injury may be more common with this procedure than with open cholecystectomy. We have encountered 17 patients with a biliary leak among 465 patients undergoing laparoscopic cholecystectomy, the diagnosis being established by clinical and radiographic parameters. The most common site of leakage was the cystic duct stump. Patients underwent endoscopic sphincterotomy and biliary stent placement, with an overall success rate of 96%. No morbidity or mortality related to the endoscopic procedures was encountered. We conclude that biliary leakage after laparoscopic cholecystectomy is uncommon. When it occurs, it can be treated safely and efficaciously by endoscopic means.
- Published
- 1994
- Full Text
- View/download PDF
6. A prospective trial of colchicine for primary biliary cirrhosis.
- Author
-
Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, and Eagen KA
- Subjects
- Alkaline Phosphatase blood, Bilirubin blood, Cholesterol blood, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Liver pathology, Liver Cirrhosis, Biliary blood, Liver Cirrhosis, Biliary pathology, Male, Middle Aged, Prospective Studies, Random Allocation, Serum Albumin analysis, Transaminases blood, Colchicine therapeutic use, Liver Cirrhosis, Biliary drug therapy
- Abstract
We entered 60 patients with primary biliary cirrhosis in a double-blind randomized controlled trial to determine whether colchicine is therapeutically effective. Thirty patients had early disease (Stages 1 and 2), and 30 had advanced disease (Stages 3 and 4). Fifteen patients with early disease and 15 with advanced disease received colchicine (0.6 mg twice daily), and the remainder received placebo. Patients were studied about every two months; those remaining in the blind phase at two years underwent repeat liver biopsy and were then placed on open-label colchicine (0.6 mg twice daily). With a few exceptions, the results in patients with early disease were similar to those in patients with advanced disease; hence, data on patients in all stages were combined in the main analysis. During the two-year study period the colchicine-treated patients, as compared with the placebo-treated patients, had improvement in levels of serum albumin, serum bilirubin, alkaline phosphatase, cholesterol, and aminotransferases. However, there was no such improvement in the severity of symptoms or physical findings; moreover, there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups. At four years after entry, the cumulative mortality from liver disease was 21 percent in patients given colchicine and 47 percent in those given placebo (P = 0.05). The only side effect of colchicine was diarrhea, noted in three patients. The consistent and significant improvement in a number of markers of liver disease and the apparent decreased mortality from liver disease suggest that colchicine may provide some long-term clinical benefit in patients with primary biliary cirrhosis. However, the failure of colchicine to reduce hepatic inflammation and fibrosis leaves uncertain the effect of the drug on the longterm outcome of this disease.
- Published
- 1986
- Full Text
- View/download PDF
7. The SCOPE of things to come.
- Author
-
Hirsch GS
- Subjects
- Hospital Bed Capacity, 300 to 499, Ohio, Awards and Prizes, Hospitals, Osteopathic organization & administration, Hospitals, Special organization & administration, Periodicals as Topic, Public Relations
- Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.